Funding round · Biotech
Omnio raises €2.9m to prepare chronic-wound therapy for clinical studies
Existing shareholders backed the Swedish biotech’s manufacturing and toxicology work.
Omnio announced an oversubscribed €2.9 million financing on 1 October 2026 from existing investors and shareholders. The company did not name individual backers.
The Swedish biotech will use the funding for a GMP manufacturing batch, toxicology studies and clinical trial applications for its plasminogen-based therapy. It aims to begin a Phase I/IIa study in diabetic foot ulcers during 2027.
Use of funds
Produce GMP batch
Conduct toxicology studies
Prepare clinical trial applications
Funding history
Funding round · This round€2.9M
Funding round~€4.3M